Gritstone bio, Inc. (GRTS)

NASDAQ: GRTS · IEX Real-Time Price · USD
1.53
+0.23 (17.69%)
At close: Dec 1, 2023, 4:00 PM
1.55
+0.02 (1.31%)
Pre-market: Dec 4, 2023, 6:17 AM EST
17.69%
Market Cap 145.87M
Revenue (ttm) 10.23M
Net Income (ttm) -138.96M
Shares Out 95.34M
EPS (ttm) -1.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,782,906
Open 1.32
Previous Close 1.30
Day's Range 1.28 - 1.55
52-Week Range 1.14 - 4.05
Beta 0.63
Analysts Strong Buy
Price Target 7.33 (+379.09%)
Earnings Date Nov 8, 2023

About GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 28, 2018
Employees 233
Stock Exchange NASDAQ
Ticker Symbol GRTS
Full Company Profile

Financial Performance

In 2022, Gritstone bio's revenue was $19.95 million, a decrease of -58.63% compared to the previous year's $48.21 million. Losses were -$119.69 million, 59.4% more than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for GRTS stock is "Strong Buy." The 12-month stock price forecast is $7.33, which is an increase of 379.09% from the latest price.

Price Target
$7.33
(379.09% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

26 days ago - GlobeNewsWire

Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio's Next Generation COVID-19 Vaccine

-- High neutralizing antibody (nAb) responses sustained through at least 12 months, highlighting potential for durable clinical protection -- -- T cell responses to Spike plus other viral targets obse...

7 weeks ago - GlobeNewsWire

Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023

EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced re...

2 months ago - GlobeNewsWire

Gritstone bio wins $433 million US award for COVID vaccine study

Gritstone bio on Wednesday secured a $433 million contract by the U.S. government to conduct a mid-stage study of its self-amplifying mRNA COVID-19 vaccine candidate.

2 months ago - Reuters

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433M

2 months ago - GlobeNewsWire

Gritstone bio to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced t...

3 months ago - GlobeNewsWire

Gritstone bio and Genevant Sciences Announce Option and License Agreement

Agreement provides nonexclusive access to Genevant's leading LNP technology for use with Gritstone bio's self-amplifying RNA technology in wide array of infectious disease vaccines

3 months ago - GlobeNewsWire

Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

-- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cancer vaccine [PCV]) in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); prelimi...

4 months ago - GlobeNewsWire

Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project

EMERYVILLE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

4 months ago - GlobeNewsWire

Gritstone bio Announces Publication of Interim Results from Phase 1 Study of Self-amplifying mRNA (samRNA) Vaccine Against COVID-19 in Nature Communications

-- Potent and durable immunogenicity achieved with low dose self-amplifying mRNA vaccine (samRNA) candidate -- -- Immunity boosted for at least 6 months in previously vaccinated-older adults (administ...

6 months ago - GlobeNewsWire

Gritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023

EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it ...

7 months ago - GlobeNewsWire

Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)

-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for at least 6 months, including variant cross-reactive nAb, in previously unvaccinat...

8 months ago - GlobeNewsWire

Gritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual Meeting

-- Longitudinal analysis of GRANITE recipients (personalized vaccine candidate now in Phase 2/3 for MSS-CRC) demonstrates vaccine-elicited priming and boosting of antigen-specific T cell populations a...

8 months ago - GlobeNewsWire

Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023

EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced m...

8 months ago - GlobeNewsWire

Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting

EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced m...

9 months ago - GlobeNewsWire

Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

-- Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals f...

9 months ago - GlobeNewsWire

Gritstone bio to Participate in 43rd Annual Cowen Healthcare Conference

EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced th...

9 months ago - GlobeNewsWire

Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination

-- NCI will lead the Phase 1 study using Gritstone's proprietary “off the shelf” vaccine technology for mutant KRAS solid tumors -- -- NCI will lead the Phase 1 study using Gritstone's proprietary “of...

10 months ago - GlobeNewsWire

Gritstone bio to Present at 41st Annual J.P. Morgan Healthcare Conference

EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced th...

1 year ago - GlobeNewsWire

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

1 year ago - GlobeNewsWire

Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)

-- Patents support Gritstone's pioneering work in the application of next-generation samRNA vaccine technology in oncology and infectious disease -- -- Patents support Gritstone's pioneering work in t...

1 year ago - GlobeNewsWire

Gritstone to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

1 year ago - GlobeNewsWire

Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update

-- Two Phase 1 CORAL (SARS-CoV-2) studies deliver positive results, provide further proof-of-concept for application of self-amplifying mRNA (samRNA) as infectious disease vaccine platform -- -- Initi...

1 year ago - GlobeNewsWire

Gritstone bio Announces Private Placement of $45.0 Million

EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

1 year ago - GlobeNewsWire

Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases

-- New data from CORAL-BOOST study demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination -- -- Interim results from CORAL-CE...

1 year ago - GlobeNewsWire